New pill shows promise for MS control in early trial
NCT ID NCT06083753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental oral drug called PIPE-307 in 182 adults with relapsing-remitting multiple sclerosis (MS). Participants took either a low or high dose of PIPE-307 or a placebo daily for about 30 weeks, alongside their usual MS medication. The goal was to see if the drug is safe and can improve vision and physical function. The trial is now complete, and results will show whether PIPE-307 deserves further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PIPE-307 (oral drug)
What this could lead to
If successful, PIPE-307 could offer a new add-on option to help control relapsing-remitting MS and potentially improve vision and mobility.
What could go wrong
This is an early Phase 2 trial with only 182 people, so results may not confirm benefit. The drug is tested as an add-on, not a standalone treatment, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alta Bates Summit Medical Center
Berkeley, California, 94705, United States
-
Aqualane Clinical Research
Naples, Florida, 34105, United States
-
Arizona Neuroscience Research, LLC
Phoenix, Arizona, 85032, United States
-
Bhupesh Dihenia, MD, PA
Lubbock, Texas, 79410, United States
-
Clinical Trial Network
Houston, Texas, 77074, United States
-
Colorado Springs Neurological Associates
Colorado Springs, Colorado, 80907, United States
-
Dent Neurologic Institute
Amherst, New York, 14226, United States
-
MS and Neuromuscular Center of Excellence
Clearwater, Florida, 33761, United States
-
Multicare Neuroscience Center of Washington
Tacoma, Washington, 98405, United States
-
Neurological Associates of Long Island, P.C.
Lake Success, New York, 11042, United States
-
Neurology Center of New England P.C.
Foxborough, Massachusetts, 02035, United States
-
Oklahoma Research Foundation - MS Center of Excellence
Oklahoma City, Oklahoma, 73104, United States
-
Shepherd Center
Atlanta, Georgia, 30309, United States
-
Sibyl Wray Neurology PC
Knoxville, Tennessee, 37922, United States
-
UW Medicine MS Center
Seattle, Washington, 98133, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of New Mexico/Health Science Center/MIND Imaging Center/MS Specialty Clinic
Albuquerque, New Mexico, 87106, United States
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Xenosciences
Phoenix, Arizona, 85004, United States